Multinational electronics and medical device manufacturer Philips has made headlines lately for all the wrong reasons. The recent recall of its SPECT BrightView nuclear imaging system is the ...

A group of over 100 institutional investors have written to Dutch medical technology company Philips demanding compensation of €800 million for “significant losses to shareholders” over the sleep ...

The Class I recall, the FDA’s severest classification, is a correction and does not require removing devices from where they are used or sold. Philips started the recall on Nov. 20, 2024 ...

The deal includes a licensing agreement that allows the sold business to use the Philips brand for up to 15 years.

This is not the only recall the company is dealing with. Philips’ Respironics business has been facing issues with some of its sleep apnea products since June 2021 when it issued a recall of 15 ...

Philips will sell its emergency care business to investment firm Bridgefield Capital for an undisclosed amount. The deal is ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect cases of hidden, transient arrhythmias that may only last minutes at a time.

Philips is recalling the software associated with its mobile cardiac outpatient telemetry devices after 109 patient injuries and two patient deaths, a Jan. 13 FDA recall notice said. The software ...

Unlike conventional single event cases, mediation in mass tort cases can be more effective if the effort is applied ...

During its first-quarter earnings report this spring, Philips, the health technology company, announced it agreed to pay $1.1 billion in a settlement over respiration and sleep apnea machines.

Investment firm Bridgefield Capital will buy the segment, which includes cardiac resuscitation and emergency care devices, ...

Philips has agreed to sell its emergency care business to Washington D.C.-based investment firm Bridgefield Capital, the companies announced on Tuesday. They did not disclose the terms of the deal ...